List of works - Sushrusha Nayak

B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study

scientific article

B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease.

scientific article published on 16 April 2013

BAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe disease

scientific article published on April 2015

Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease

scientific article published on 25 November 2015

Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies

scientific article published on 16 September 2013

GITR engagement preferentially enhances proliferation of functionally competent CD4+CD25+FoxP3+ regulatory T cells

scientific article

Glucose oxidation modulates anoikis and tumor metastasis.

scientific article

Immune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent.

scientific article

Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B.

scientific article

Induction of tolerance to factor VIII by transient co-administration with rapamycin.

scientific article published on August 2011

Manganese superoxide dismutase promotes anoikis resistance and tumor metastasis

scientific article published on 21 February 2013

Mapping the T helper cell response to acid α-glucosidase in Pompe mice

scientific article

Pompe disease gene therapy.

scientific article

Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B.

scientific article

Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice.

scientific article published on 12 December 2013

Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg.

scientific article published on April 2015

Targeted approaches to induce immune tolerance for Pompe disease therapy

scientific article

Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity

scientific article

List of works by Sushrusha Nayak

B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study

B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease.

BAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe disease

Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease

Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies

GITR engagement preferentially enhances proliferation of functionally competent CD4+CD25+FoxP3+ regulatory T cells

Glucose oxidation modulates anoikis and tumor metastasis.

Immune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent.

Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B.

Induction of tolerance to factor VIII by transient co-administration with rapamycin.

Manganese superoxide dismutase promotes anoikis resistance and tumor metastasis

Mapping the T helper cell response to acid α-glucosidase in Pompe mice

Pompe disease gene therapy.

Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B.

Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice.

Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg.

Targeted approaches to induce immune tolerance for Pompe disease therapy

Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity